

**Task History**

June 22, 2011 10:26 PM

**Saved answer set '10581274' opened**

Answer set 6 created with 2 reference answers from CAPLUS

**Detailed display from Answer set 6 of Highly Potent, Orally Available Anti-inflammatory Broad-Spectrum Chemokine Inhibitors**

## Highly Potent, Orally Available Anti-inflammatory Broad-Spectrum Chemokine Inhibitors

By: Fox, David J.; Reckless, Jill; Lingard, Hannah; Warren, Stuart; Grainger, David J.

A series of 3-acylamino-caprolactams are inhibitors of chemokine-induced chemotaxis. Branching of the side chain  $\alpha$ -carbon provides highly potent inhibitors of a range of CC and CXC chemokines. The most potent compd. has an ED50 of 40 pM. Selected compds. were tested in an in vivo inflammatory assay, and the best compd. reduces TNF- $\alpha$  levels with an ED50 of 0.1  $\mu$ g/kg when administered by either s.c. injection or oral delivery.

### Indexing

Pharmacology (Section 1-3)

### Concepts

Anti-inflammatory agents

Cell migration

Chemotaxis

Human

Inflammation

Neutrophil

Structure-activity relationship

oral antiinflammatory broad-spectrum chemokine inhibitors

CC chemokines

CXC chemokines

Chemokines

Interleukin 8

Macrophage inflammatory protein 1 $\alpha$

Monocyte chemoattractant protein-1

RANTES(chemokine)

Tumor necrosis factors

oral antiinflammatory broad-spectrum chemokine inhibitors

Biological study, unclassified; Biological study

### Substances

853905-44-9P

oral antiinflammatory broad-spectrum chemokine inhibitors

Drug mechanism of action; Pharmacological activity; Reactant; Synthetic preparation; Therapeutic use;

Biological study; Preparation; Uses; Reactant or reagent

### Source

Journal of Medicinal

Chemistry

Volume 52

Issue 11

Pages 3591-3595

Journal

2009

CODEN: JMCMAR

ISSN: 0022-2623

DOI:

10.1021/jm900133w

### Company/Organization

Department of Chemistry

University of Cambridge

Cambridge, UK CB2

1EW

### Accession Number

2009:565761

CAN 151:23962

CAPLUS

### Publisher

American Chemical

Society

### Language

English

726187-67-3P  
 853905-34-7P  
 853905-39-2P  
 853905-40-5P  
 853905-41-6P  
 853905-42-7P  
 853905-45-0P  
 853905-59-6P  
 853905-60-9P  
 853905-61-0P  
 853905-62-1P  
 853905-68-7P  
 853905-72-3P  
 876063-97-7P  
 876063-98-8P  
 876063-99-9P  
 876064-01-6P  
 876064-02-7P  
 876064-03-8P  
 1160115-32-1P  
 1160115-34-3P

oral antiinflammatory broad-spectrum chemokine inhibitors

Drug mechanism of action; Pharmacological activity; Synthetic preparation; Therapeutic use; Biological study; Preparation; Uses

108-18-9 Diisopropylamine  
 112-31-2 Decanal  
 547-63-7 Methyl isobutyrate  
 671-42-1  
 870-63-3  
 924-50-5 Methyl 3,3-dimethylacrylate  
 2094-72-6 1-Adamantanecarbonyl chloride  
 2719-27-9 Cyclohexanecarbonyl chloride  
 2890-61-1 1-Methylcyclohexanecarbonyl chloride  
 3282-30-2 2,2-Dimethylpropionyl chloride  
 4301-04-6  
 5856-77-9 2,2-Dimethylbutyryl chloride  
 15721-22-9 2,2-Dimethylpentanoyl chloride  
 19835-38-2  
 21568-87-6  
 26081-07-2  
 28957-33-7  
 36278-22-5 1-Cyclohexenecarbonyl chloride  
 39482-46-7 2,2-Dimethyl-4-pentenoyl chloride  
 39691-62-8 Nonylmagnesium bromide  
 50321-59-0  
 60631-34-7 2,2-Dimethyldodecanoyl chloride  
 67589-90-6  
 73152-73-5

oral antiinflammatory broad-spectrum chemokine inhibitors

Reactant; Reactant or reagent

2198-82-5P 2,2,5-Trimethyl-4-hexenoic acid  
53663-29-9P (E)-2-Methyldodec-2-enoic acid  
66478-19-1P  
102944-03-6P 3,3-Dimethyldodecanoic acid  
476690-74-3P (E)-Ethyl 2-methyldodec-2-enoate  
853905-71-2P  
1017249-22-7P  
1017249-74-9P

oral antiinflammatory broad-spectrum chemokine inhibitors

Reactant; Synthetic preparation; Preparation; Reactant or reagent

### Supplementary Terms

oral antiinflammatory chemokine inhibitor structure

### Citations

- 1a) Gerard, C; Nat Immunol 2001, 2, 108
- 1b) Horuk, R; Cytokine Growth Factor Rev 2001, 12, 313
- 1c) Rollins, B; Blood 1997, 90, 909
- 1d) Luster, A; N Engl J Med 1998, 338, 436
- 1e) Thelen, M; Nat Immunol 2001, 2, 129
- 2) Viola, A; Annu Rev Pharmacol Toxicol 2008, 48, 171
- 3a) Ribeiro, S; Pharmacol Ther 2005, 107, 44
- 3b) Carter, P; Curr Opin Chem Biol 2002, 6, 510
- 3c) Allen, S; Annu Rev Immunol 2007, 25, 787
- 4a) Vaidehi, N; J Biol Chem 2006, 281, 27613
- 4b) Pasternak, A; Bioorg Med Chem Lett 2008, 18, 1374
- 4c) Santella, L; Bioorg Med Chem Lett 2008, 18, 576
- 4d) Thoma, G; Bioorg Med Chem Lett 2008, 18, 2000
- 5a) Vandercappellen, J; Cancer Lett 2008, 267, 226
- 5b) Biju, P; Bioorg Med Chem Lett 2008, 18, 228
- 6a) Reckless, J; Biochem J 1999, 340, 803
- 6b) Reckless, J; Immunology 2001, 103, 244
- 7a) Fox, D; J Med Chem 2002, 45, 360
- 7b) Fox, D; J Med Chem 2005, 48, 867
- 8a) Grainger, D; Biochem Pharmacol 2003, 65, 1027
- 8b) Naidu, B; Ann Thorac Surg 2003, 75, 1118
- 8c) Wilbert, S; Anal Biochem 2000, 278, 14
- 9) Schroff, R; Mini-Rev Med Chem 2005, 5, 849
- 10) Frow, E; Med Res Rev 2004, 24, 276
- 1) Boyle, W; J Am Chem Soc 1979, 44, 4841
- 2) Rezier, E; J Med Chem 1997, 40, 3508
- 3) Reckless, J; Biochem J 1999, 340, 803
- 4) Fox, D; J Med Chem 2002, 45, 360
- 5) Fox, D; J Med Chem 2005, 48, 867
- 6) Frow, E; Med Res Rev 2004, 24, 267

### Tags

0 Tags

### Comments

0 Comments

Copyright © 2011 American Chemical Society (ACS). All Rights Reserved.